Wilmington, Delaware, United States, July 05, 2023 (GLOBE NEWSWIRE) -- The global DNA repair drugs market was valued at US$ 5.9 Bn in 2022 and is projected to reach US$ 10.4 Bn by 2031 with CAGR of 6.5%. Rise in usage of combination therapy in the treatment of drug-resistant tumors is anticipated to broaden market outlook.
Pressing need for new therapeutic approaches to cancer therapies is fueling the development of inhibitors of DNA repair pathways. This, in turn, is propelling industry investments in the DNA repair drugs market.
Download Sample Copy with Graphs & List of Figures@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=77165
“Connect with our team of research specialists and unlock the optimal solution for driving your business growth”
Rise in adoption of chemotherapy in cancer treatments is a key market trend that is encouraging clinical studies on DNA damage repair (DDR)-based drugs. Significant demand for DDR-related drugs in the treatment of a range of malignant tumors presents significant growth opportunities for companies in the market.
Key Findings of Study
- Significant Research in DNA Repair Pathway to Bolster Development of Novel Drugs: Rise in R&D activities in improving the therapeutic outcomes of current chemotherapies and radiotherapies is expected to accelerate market development. Need for novel anticancer agents in chemotherapies presents significant market opportunities. Identification of somatic mutations in advanced breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer is likely to bolster the usage of DNA repair drugs in cancer therapy.
- High Preference for DNA Repair Tablet Dosage Form: Based on dosage form, the tablets segment is projected to account for dominant market share during the forecast period. Rise in availability of DNA repair tablets in retail pharmacies is anticipated to bolster the market.
- Rise in Demand for PARP Inhibitors to Target DNA Damage Repair: Considerable usage of PARP inhibitors to target homologous recombination repair (HRR) pathways is expected to augment the market size over the next few years. PARP inhibitors are used to target tumors extensively in metastatic prostate cancer and triple-negative breast cancer. Significant utilization of a range of PARP inhibitors, such as olaparib, niraparib and rucaparib, in cancer patients with BRCA1/2 mutation and deficiency in HRR is likely to strengthen market value in the next few years.
Key Growth Drivers of DNA Repair Drugs Market
- Rise in incidence of cancer, especially rapid increase with age, in several countries is a key driver of the market. Cancers of the breast, lung, colon and rectum and prostate and the resulting metastases pose global health burden, as these account for significant percentage of deaths from cancer. High prevalence of solid tumors, especially sarcomas, carcinomas, and lymphomas, is propelling research in DNA damage-based therapies.
- Rapid development of technologies used in high-throughput sequence analysis of DNA, such as CRISPR/Cas9-based editing platform, is anticipated to drive the DNA repair drugs market. Usage of technologies has enabled researchers to generate a range of DNA damage response (DDR)-agents.
For In-Depth Competitive Analysis, Buy this Report Now@ https://www.transparencymarketresearch.com/checkout.php?rep_id=77165<ype=S
Regional Landscape
North America is projected to account for dominant market share during the forecast period. Focus of research studies on improving the current treatment of refractory and drug-resistant tumors, especially solid tumors, is broadening market outlook in North America. Rise in adoption of immunotherapy in a range of cancers, such as breast cancer, ovarian cancer, pancreatic cancer, and blood cancer, is likely to create lucrative business opportunities for companies in the region in the near future. Innovation in DNA repair strategies is expected to offer significant growth opportunities to market players in the next few years. High prevalence of solid cancers in North America presents significant untapped opportunities for companies.
The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period. Surge in development of drugs that target DNA damage repair in the next-generation of cancer therapies is anticipated to bolster opportunities for companies in the market in the region. Increase in clinical trials in genomic biomarkers is projected to create new business opportunities for market players in Asia Pacific.
Competition Landscape
The business landscape is highly consolidated, with a small number of companies accounting for majority stake. Key players are adopting the strategy of continuous R&D activities to stay ahead of their competitors.
Leading players in the DNA repair drugs market are
- AstraZeneca plc
- Clovis Oncology
- Pfizer Inc.
- Merck & Co. Inc
- Novartis AG
- Johnson & Johnson
- GlaxoSmithKline plc
- Bristol Meyers Squibb Company
Budget constraints? Contact us for special Pricing at https://www.transparencymarketresearch.com/sample/sample.php?flag=d&rep_id=77165
Segmentation
The global DNA repair drugs market is segmented based on
Drug Type
- PARP Inhibitors
- Alkylating Agents
- Others
Application
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Head and Neck Cancer
- Others
Dosage Form
- Tablets
- Capsules
- Injectables
Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Middle East & Africa
- Latin America
- Asia Pacific
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
Contact:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com
